Patent · US Active

Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitors

US9255106B2 · kind B2 · utility

1Cited by

0References

14Claims

0Family size

Assignee

SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES · CN

Inventors

Ao Zhang · Beijing, CN
Zehong Miao · Shanghai, CN
Na Ye · 安丰镇, CN
Xiajuan Huan · Shanghai, CN
Zilan Song · Shanghai, CN
Chuanhuizi Chen · Shanghai, CN
Yi Chen · Shanghai, CN
Jian Ding · Shanghai, CN

Key dates

Filing date	Jul 24, 2013
Grant date	Feb 9, 2016
Priority date	—
Expiry date	Jul 24, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a piperazinotriazole compound represented by general formula I or a pharmaceutically acceptable salt, stereoisomer, tautomer or hydrate thereof. Also provided are a pharmaceutical composition comprising the compound, a method for preparing the compound and a method of use thereof as a high-selectivity poly(adenosine diphosphate-ribose)polymerase-1 (PARP-1) inhibitor in the preparation of drugs for the prevention and/or treatment of PARP-related diseases.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.